文献速递妇科

复方瑞卢戈利治疗子宫内膜异位症相关疼痛的两年疗效与安全性:SPIRIT开放标签扩展研究

Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study.
PubMed 文献 · Hum Reprod · 2024-01-01

SPIRIT开放标签扩展研究显示,复方瑞卢戈利(瑞卢戈利40mg+雌二醇1mg+醋酸炔诺酮0.5mg)治疗子宫内膜异位症相关疼痛长达2年,痛经和NMPP应答率分别为84.8%和75.8%,骨密度在初始下降<1%后保持稳定,安全性与前24周一致。

要点

  • 治疗104周/结束时痛经应答率84.8%,NMPP应答率75.8%。
  • 91%患者停用阿片类药物,75%停用镇痛药。
  • 骨密度在24周下降<1%后于36周趋于稳定并维持至104周。

核心结论

  • 复方瑞卢戈利治疗可长达2年持续改善子宫内膜异位症相关疼痛和功能,安全性与前24周一致,骨密度保持稳定。

研究设计与样本

  • 开放标签、单臂、长期扩展研究,纳入完成24周SPIRIT 1和2关键研究的绝经前子宫内膜异位症患者,额外接受最多80周复方瑞卢戈利治疗,2018年5月至2023年1月进行。
  • 共1261例随机化患者,1044例完成关键研究,802例入组扩展研究,681例完成52周治疗,501例完成104周治疗。
  • 按关键研究原随机分组分析:复方瑞卢戈利组、延迟复方瑞卢戈利组(瑞卢戈利40mg单药12周后复方瑞卢戈利)或安慰剂→复方瑞卢戈利组。

主要发现

  • 在关键研究基线随机至复方瑞卢戈利组并继续扩展研究的患者(N=277)中,第104周/结束时痛经应答率为84.8%,NMPP应答率为75.8%。
  • 性交痛和EHP-30疼痛域功能改善持续2年。
  • 第104周/结束时91%患者无阿片类药物使用,75%患者无镇痛药使用。
  • 24周骨密度最小二乘均值下降<1%,36周趋于稳定并维持至104周。
  • 安慰剂→复方瑞卢戈利组和延迟复方瑞卢戈利组的疗效和安全性结果总体一致。

关键数值与推荐

  • 痛经应答定义为NRS评分较基线下降≥2.8分且镇痛药使用不增加。
  • NMPP应答定义为NRS评分较基线下降≥2.1分且镇痛药使用不增加。

临床怎么用

  • 复方瑞卢戈利为需要长期有效药物治疗的子宫内膜异位症患者提供额外选择,可减少阿片类药物需求并改善生活质量。
  • 作者认为该研究结果可能有助于支持寻求长期有效药物管理的子宫内膜异位症女性的照护。

局限性

  • 扩展期80周为开放标签研究,无对照组。
  • 802例入组扩展研究的患者中,681例(84.9%)完成52周治疗,501例(62.5%)完成104周治疗。
  • 目前无与其他激素药物的对比数据。
  • 37.4%的研究人群提前终止参与。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: What is the efficacy and safety of long-term treatment (up to 2 years) with relugolix combination therapy (CT) in women with moderate to severe endometriosis-associated pain? SUMMARY ANSWER: For up to 2 years, treatment with relugolix CT improved menstrual and non-menstrual pain, dyspareunia, and function in women with endometriosis; after an initial decline of <1%, the mean bone mineral density (BMD) remained stable with continued treatment. WHAT IS KNOWN ALREADY: Endometriosis is a chronic condition characterized by symptoms of dysmenorrhea, non-menstrual pelvic pain (NMPP), and dyspareunia, which have a substantial impact on the lives of affected women, their partners, and families. SPIRIT 1 and 2 were phase 3, randomized, double-blind, placebo-controlled studies of once-daily relugolix CT (relugolix 40 mg, oestradiol 1 mg, norethisterone acetate 0.5 mg) in premenopausal women (age 18-50 years) with endometriosis and moderate-to-severe dysmenorrhea and NMPP. These trials demonstrated a significant improvement of dysmenorrhea, NMPP, and dyspareunia in women treated with relugolix CT, with minimal decline (<1%) in BMD versus placebo at 24 weeks. STUDY DESIGN, SIZE, DURATION: Patients participating in this open-label, single-arm, long-term extension (LTE) study of the 24-week SPIRIT pivotal studies (SPIRIT 1 and 2) received up to an additional 80 weeks of once-daily oral relugolix CT treatment between May 2018 and January 2023. PARTICIPANTS/MATERIALS, SETTING, METHODS: Premenopausal women with confirmed endometriosis and moderate to severe dysmenorrhea and NMPP who completed the 24-week pivotal studies (SPIRIT 1 and 2 trials; Giudice et al., 2022) and who met all entry criteria were eligible to enrol. Two-year results were analysed by treatment group based on original randomization in pivotal studies: relugolix CT, delayed relugolix CT (relugolix 40 mg monotherapy for 12 weeks, followed by relugolix CT), or placebo→relugolix CT (placebo for 24 weeks followed by relugolix CT). The primary endpoints of the LTE study were the proportion of dysmenorrhea and NMPP responders at Week 52 and Week 104/end-of-treatment (EOT). A responder was a participant who achieved a predefined, clinically meaningful reduction from baseline in Numerical Rating Scale (NRS) scores (0 = no pain, 10 = worst pain imaginable) for the specific pain type with no increase in analgesic use. The predefined clinically meaningful threshold for dysmenorrhea was 2.8 points and for NMPP was 2.1 points. Secondary efficacy endpoints included change from baseline in Endometriosis Health Profile-30 (EHP-30) pain domain scores, a measure of the effects of endometriosis-associated pain on daily activities (function), NRS scores for dysmenorrhea, NMPP, dyspareunia, and overall pelvic pain, and analgesic/opioid use. Safety endpoints included adverse events and changes in BMD. MAIN RESULTS AND THE ROLE OF CHANCE: Of 1261 randomized patients, 1044 completed the pivotal studies, 802 enrolled in the LTE, 681 completed 52 weeks of treatment, and 501 completed 104 weeks of treatment. Demographics and baseline characteristics of the extension population were consistent with those of the original randomized population. Among patients randomized to relugolix CT at pivotal study baseline who continued in the LTE (N = 277), sustained improvements in endometriosis-associated pain were demonstrated through 104 weeks. The proportion of responders at Week 104/EOT for dysmenorrhea and NMPP was 84.8% and 75.8%, respectively. Decreases in dyspareunia and improvement in function assessed by EHP-30 pain domain were also sustained over 2 years. At Week 104/EOT, 91% of patients were opioid-free and 75% of patients were analgesic-free. Relugolix CT over 104 weeks was well tolerated with a safety profile consistent with that observed over the first 24 weeks. After initial least squares mean BMD loss <1% at Week 24, BMD plateaued at Week 36 and was sustained for the duration of 104 weeks of treatment. Efficacy and safety results were generally consistent in women in the placebo→relugolix CT and delayed relugolix CT groups. LIMITATIONS, REASONS FOR CAUTION: The study was conducted as an open-label study without a control group over the 80 weeks of the extension period. Of the 802 patients who were enrolled in this LTE study, 681 patients (84.9%) and 501 patients (62.5%) of patients completed 52 and 104 weeks of treatment, respectively. In addition, there currently are no comparative data to other hormonal medications. Finally, a third (37.4%) of the study population terminated participation early. WIDER IMPLICATIONS OF THE FINDINGS: In conclusion, relugolix CT offers an additional option to help address an important unmet clinical need for effective, safe, and well-tolerated medical treatments for endometriosis that can be used longer-term, reducing the need for opioids and improving quality of life. The findings from this study may help support the care of women with endometriosis seeking longer-term effective medical management of their symptoms. STUDY FUNDING/COMPETING INTEREST(S): This study was funded by Myovant Sciences GmbH (now Sumitomo Pharma Switzerland GmbH). C.M.B. reports fees from Myovant, grants from Bayer Healthcare, fees from ObsEva, and Chair of ESHRE Endometriosis Guideline Group (all funds went to the University of Oxford); N.P.J. reports personal fees from Myovant Sciences, during the conduct of the study, personal fees from Guerbet, personal fees from Organon, personal fees from Roche Diagnostics; S.A.-S. reports personal fees from Myovant Sciences, personal fees from Bayer, personal fees from Abbvie, personal fees from UpToDate; J.S.P., and R.B.W. are employees and shareholders of Myovant Sciences; J.C.A.F. and S.J.I. are shareholders of Myovant Sciences (but at time of publicaion are no longer employess of Myovant Sciences); M.S.A. and K.W. have no conflicts to declare; V.M. is a consultant to Myovant; L.C.G. reports personal fees from Myovant Sciences, Inc and Bayer. The authors did not receive compensation for manuscript writing, review, and revision. TRIAL REGISTRATION NUMBER: NCT03654274.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Becker CM, Johnson NP, As-Sanie S, et al. Two-year efficacy and safety of relugolix combination therapy in women with endometriosis-associated pain: SPIRIT open-label extension study. Hum Reprod. 2024. PMID: 38243752. doi:10.1093/humrep/dead263

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。